Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

April 27, 2021 Auto Bot approval, Biocon Biologics, Biosimilar, Biosimilars, European Commission, Viatris 0

Shots:

  • The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, NSCLC, glioblastoma, ovarian, cervical, and renal cancer as part of a specific regimen
  • The approval follows CHMP’s positive opinion and is valid in all EU Member States as well as in the EEA countries Iceland, Liechtenstein, and Norway
  • The approval will strengthen Biocon’s portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim

Click here to­ read full press release/ article | Ref: Biocon | Image: Medicircle

The post Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab) first appeared on PharmaShots.